Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial

The Lancet

Volumn 380, Issue 9852, 2012, Pages 1482-1490

  Sabate, Manel ^a   Cequier, Angel ^b   Iñiguez, Andrés ^c   Serra, Antonio ^d   Hernandez Antolin, Rosana ^e   Mainar, Vicente ^f   Valgimigli, Marco ^g   Tespili, Maurizio ^h   Den Heijer, Pieter ⁱ   Bethencourt, Armando ^j   Vazquez, Nicolás ^k   Gómez Hospital, Joan Antoni ^b   Baz, José Antonio ^c   Martin Yuste, Victoria ^d   Van Geuns, Robert Jan ^l   Alfonso, Fernando ^e   Bordes, Pascual ^f   Tebaldi, Matteo ^g   Masotti, Monica ^a   Silvestro, Antonio ^h   Backx, Bianca ^m   Brugaletta, Salvatore ^m   Van Es, Gerrit Anne ^m   Serruys, Patrick W ^l   more..

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL DO MEIXOEIRO   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^g UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^h University Hospital Bolognini Seriate   (Italy)

ⁱ AMPHIA HOSPITAL   (Netherlands)

^j HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^k HOSPITAL JUAN CANALEJO   (Spain)

^l ERASMUS MEDICAL CENTER   (Netherlands)

^m CARDIALYSIS   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS;

ADULT; ARTICLE; BARE METAL STENT; BLEEDING; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; HEART DEATH; HEART REINFARCTION; HUMAN; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TELECONSULTATION;

EID: 84867890841     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61223-9     Document Type: Article

References (39)

1. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31: 2501-55.
2. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355: 1093-104.
3. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 355: 1105-13.
4. Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 2008; 299: 1788-99.
5. Violini R, Musto C, De Felice F, et al. Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial. J Am Coll Cardiol 2010; 55: 810-14.
6. Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011; 377: 2193-204.
7. Kukreja N, Onuma Y, Garcia-Garcia HM, Daemen J, van Domburg R, Serruys P W. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents. JACC Cardiovasc Interv 2009; 2: 534-41.
8. Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007; 28: 2706-13.
9. Daemen J, Tanimoto S, Garcia-Garcia HM, et al. Comparison of three-year clinical outcome of sirolimus-and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol 2007; 99: 1027-32.
10. Spaulding C, Teiger E, Commeau P, et al. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallO ON angioplasty). JACC Cardiovasc Interv 2011; 4: 14-23.
11. Valgimigli M, Campo G, Arcozzi C, et al. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. J Am Coll Cardiol 2007; 50: 138-45.
12. Stone GW, Witzenbichler B, Guagliumi G, et al, for HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011; 377: 2193-204.
13. Iakovou I, Schmidt T, Bonizzoni E, Ge L, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-30.
14. Urban P, Gershlick AH, Guagliumi G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006; 113: 1434-41.
15. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007; 369: 667-78.
16. Steg PG, Fox KA, Eagle KA, et al. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J 2009; 30: 321-29.
17. Urban P, Abizaid A, Banning A, et al. Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT (Multi-Center Post-Market Surveillance) registry. J Am Coll Cardiol 2011; 57: 1445-54.
18. de la Torre Hernandez JM, Alfonso F, Gimeno F, et al. Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2 (Estudio Espanol Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2). JACC Cardiovasc Interv 2010; 3: 911-19.
19. Dirksen MT, Vink MA, Suttorp MJ, et al. Two year follow-up after primary PCI with a paclitaxel-eluting stent versus a bare-metal stent for acute ST-elevation myocardial infarction (the PASSION trial): a follow-up study. Euro Intervention 2008; 4: 64-70.
20. Kaltoft A, Kelbaek H, Thuesen L, et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. J Am Coll Cardiol 2010; 56: 641-45.
21. Piscione F, Piccolo R, Cassese S, et al. effect of drug-eluting stents in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis of randomised trials and an adjusted indirect comparison. Euro Intervention 2010; 5: 853-60.
22. Sheiban I, Villata G, Bollati M, Sillano D, Lotrionte M, Biondi-Zoccai G. Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V). Vasc Health Risk Manag 2008; 4: 31-38.
23. Serruys PW, Ruygrok P, Neuzner J, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. Euro Intervention 2006; 2: 286-94.
24. Planer D, Smits PC, Kereiakes DJ, et al. Comparison of everolimus-and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials. JACC Cardiovasc Interv 2011; 4: 1104-15.
25. Sabate M, Cequier A, Iniguez A, et al. Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. Euro Intervention 2011; 7: 977-84.
26. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-51.
27. Vranckx P, Cutlip DE, Mehran R, et al. Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. Addendum to the historical MI definitions used in stent studies. Euro Intervention 2010; 5: 871-74.
28. Tanimoto S, Tsuchida K, Daemen J, Boersma E. Drug-eluting stent implantation in acute myocardial infarction. Do we need another randomised trial? (TYPHOON, PASSION and HORIZONS trials). Euro Intervention 2006; 2: 23-27.
29. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001; 103: 2816-21.
30. Ruygrok PN, Melkert R, Morel MA, et al. Does angiography six months after coronary intervention influence management and outcome? Benestent II Investigators. J Am Coll Cardiol 1999; 34: 1507-11.
31. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54: 2129-38.
32. Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011; 123: 1400-09.
33. Guagliumi G, Costa MA, Sirbu V, et al. Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: optical coherence tomography substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. Circulation 2011; 123: 274-81.
34. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010; 375: 201-09.
35. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363: 136-46.
36. Raber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012; 125: 1110-21.
37. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012; 379: 1393-402.
38. Bangalore S, Kumar S, Fusaro M, et al. Short and long-term outcomes with drug eluting and bare metal coronary stents: a mixed treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012; 125: 2873-91.
39. de Boer SP, Lenzen MJ, Oemrawsingh RM, et al. Evaluating the 'all-comers' design: a comparison of participants in two 'all-comers' PCI trials with non-participants. Eur Heart J 2011; 32: 2161-67.